Announcements Trials
Browse Landscape

Status

Available 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 682Observational 141Expanded_access 3

Sponsor

Cancer Type

Thoracic 5Sarcoma 4Gastrointestinal 3Tumor-Agnostic 2Genitourinary 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Pancreatic Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

balstilimab 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Gastrointestinal × 30 days × Clear all
NCT06751524 2026-05-15

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Agenus Inc.

Available
DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT06948955 2026-05-08

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.

Available
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT07573215 2026-05-07

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Revolution Medicines, Inc.

Available
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡